Effects of Propofol on Brain Function in Patients With Parkinson's Disease

Last updated: June 25, 2023
Sponsor: Beijing Tiantan Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Propofol

Clinical Study ID

NCT05895019
ywn20220901
  • Ages 18-80
  • All Genders

Study Summary

Propofol is a short-acting general anesthetic drug commonly used in clinical practice, with rapid clinical onset of action, amnesic, anxiolytic, antiepileptic, and muscle relaxant effects. The lack of natural antioxidants in patients with Parkinson's disease and propofol's ability to protect the brain by inhibiting oxidative stress, its pharmacokinetic and pharmacodynamic properties make propofol a suitable anesthetic drug for functional stereotactic surgery in patients with Parkinson's disease. However, changes in brain functional status during propofol anesthesia in Parkinson's patients are unknown. There is a lack of data from extensive clinical studies to support the need for propofol dosing during induction of anesthesia compared with non-Parkinson patients. This study is a prospective cohort study designed to compare the differences in propofol dosing requirements during induction of propofol anesthesia in patients with PD versus non-PD and to monitor the characteristics of altered brain functional status such as EEG and cerebral blood flow autoregulation capacity in PD versus non-PD patients during the perioperative period.

Eligibility Criteria

Inclusion

Inclusion Criteria: PD group:

  1. age 18-80 years, ASA class I-III, proposed bilateral DBS surgery;
  2. primary PD, or hereditary PD, various genotypes of PD, responding well to compoundedlevodopa;
  3. informed consent obtained; Non-PD group:
  4. age 18-80 years, ASA class I-III, proposed non-neurosurgical non-cardiac surgery;
  5. no previous clearly diagnosed neurological disease or neurological dysfunction;
  6. informed consent obtained.

Exclusion

Exclusion Criteria:

  1. Obstructive sleep apnea;
  2. BMI > 30kg/m2;
  3. Estimated difficult airway;
  4. Patients with prior allergy to anesthetic drugs;
  5. Serious dysfunction of important organs (i.e. heart failure, renal or liverdysfunction);
  6. Patients with craniocerebral trauma or craniocerebral operation history resulting inincomplete skull or brain parenchyma defect;
  7. Patients with alcohol or drug addiction.

Study Design

Total Participants: 600
Treatment Group(s): 1
Primary Treatment: Propofol
Phase:
Study Start date:
June 01, 2023
Estimated Completion Date:
September 30, 2026

Connect with a study center

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.